Adrenal mass | 1, 7 |
Adrenal tumour | 112 |
Adrenalectomy | 1,112 |
AMACR | 38 |
Amino transferases | 136 |
Androgens | 31 |
Angiogenesis | 107 |
Angiomyolipoma | 74 |
Antibiotherapy | 196 |
Ascorbic acid | 107 |
Automated urine analysis | 17 |
Benign prostatic obstruction | 157 |
Bladder | 182 |
Bladder cancer | 17,104,136,177,186 |
Bleeding control | 157 |
Cancer | 64,85,182,210 |
Chemotherapy | 104,175 |
Clinicopathological features | 118 |
Council | 80 |
COVID-19 pandemic | 100 |
De ritis ratio | 136 |
Diagnosis | 17,21 |
Digit ratio | 31 |
Digital rectal examination | 215 |
Distant metastasis | 130 |
Downgrade | 35 |
Early cystectomy | 167 |
eGFR | 20 |
Embryonal | 92 |
Epididymitis | 92 |
Extraperitoneal | 165 |
Fall | 12 |
Framingham risk score | 20 |
Fusion biopsy | 60 |
Ga-68 PSMA ligand PET/CT | 151 |
Gene polymorphism | 191 |
Germ cell tumours | 146 |
Grade | 136 |
Haemoglobin | 157 |
High-risk bladder cancer | 167 |
Histopathology | 68 |
Homologous-recombination deficiency | 175 |
Immunohistochemistry | 118 |
Inferior vena cava | 162 |
Intravesical | 182 |
Intravesical recurrence | 85 |
Invasion | 215 |
Ischaemia | 124 |
Kidney tumors | 68 |
Kidney tumour | 130 |
Laparoscopic adrenalectomy | 7 |
Laparoscopy | 7,74,112,124,165,218 |
Large adrenal masses | 7 |
Learning curve | 112 |
Leiomyosarcoma | 215 |
Local recurrence | 130 |
Lymphocyte | 210 |
Marker | 177 |
MEN 2A | 42 |
Metastatic renal cancer | 162 |
Mitomycin | 182 |
Monocyte/lymphocyte ratio | 20 |
Monopolar transurethral resection | 157 |
Multidisciplinary | 80 |
Multiparametric magnetic resonance imaging | 206 |
Muscle invasive bladder cancer | 186 |
Neoadjuvant sunitinib | 162 |
Neoadjuvant therapy | 104 |
Neutrophil | 210 |
Non-muscle invasive bladder cancer | 167 |
Oncologic outcomes | 20,186 |
Orchiectomy | 64 |
Organ-sparing surgery | 1 |
Partial adrenalectomy | 1,42 |
Partial nephrectomy | 74,124,130 |
Pathology | 35 |
Pheochromocytoma | 42 |
Power Doppler ultrasonography | 200 |
Prophylactic antibiotic | 56 |
Prostate biopsy | 56,6 |
Prostate cancer | 31,35,38,49,107,151,165,175,191,196, |
200,206,215 | |
Prostate specific antigen | 35,2 |
PSA | 38,151,196 |
PSA density | 200 |
Radical cystectomy | 20,186 |
Radical nephrectomy | 162 |
Radical prostatectomy | 165,206 |
Radiotherapy | 49 |
RCC | 80 |
Recommendations | 100 |
Recurrence | 177 |
Renal angiomyolipoma | 118 |
Renal cell carcinoma | 68 |
Renal sinus invasion | 80 |
Rhabdomyosarcoma | 92 |
Risk | 12 |
Robotic surgery | 206,218 |
Secondary muscle invasive bladder cancer | 186 |
Selective ischaemia | 124 |
Seminal vesicle | 218 |
Seminal vesicle cyst | 218 |
Seminal vesicle mass | 218 |
Seminoma | 64 |
Stage | 136 |
Surgical margin positivity | 130 |
Survival | 141, 146 |
Testicular cancer | 141, 146 |
Testicular germ cell tumor | 141 |
Testis | 64,21 |
Thermo | 182 |
Timely cystectomy | 167 |
Transfusion | 157 |
Treatment | 49 |
Tumor | 64 |
Tumour thrombus | 162 |
Upgrade | 35 |
Ureters | 85 |
Urinary tract infection | 56 |
Urologic cancers | 100 |
Urologic oncology | 100 |
Urology | 12 |
Uroradiology | 80 |
Urosepsis | 60 |
Urothelial carcinoma | 85 |
VHL syndrome | 42 |
Vitamin D | 191 |
Zero-ischaemia | 124 |